PORT HUENEME, CA--(Marketwired - Oct 1, 2015) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), is pleased to provide an update on the Company's ongoing collaboration with privately-held Taiwan biopharmaceuticals manufacturer Amaran Biotechnology, Inc. ("Amaran").

The alliance between Stellar and Amaran was formed in 2013 to develop and evaluate methods for the manufacture of the OBI-822 immunotherapy, which incorporates Stellar KLH™ as the immune-stimulating carrier molecule. OBI-822 is the flagship product of OBI Pharma, Inc., a publicly-listed Taiwan biotech company. The product is currently in a late-stage multinational clinical trial for the treatment of metastatic breast cancer. Enrollment for this Phase II/III trial was completed in 2014 and OBI Pharma expects its topline results to be announced by March, 2016. OBI-822 is also in a physician-initiated Phase II clinical trial in Taiwan for the treatment of ovarian cancer. Recruitment for that trial is expected to be completed by the end of this year.

Stellar and Amaran have now completed all primary objectives of the collaboration, which include method development, formulation, and process qualification for GMP-grade Stellar KLH™ and meeting the specifications needed for the production of OBI-822. The next stage of the collaboration will involve scale-up and optimization of processes to commercial manufacturing levels, with the focus on production, quality, and regulatory requirements to support OBI Pharma's planned global Phase III trial and potential future market launch.

Additionally, Amaran recently commissioned a new state-of-the-art biological manufacturing and research center in Taiwan's Hsinchu Biomedical Science Park in Hsinchu County, Taiwan, anticipating expanded capacity for the production of active immunotherapies, such as OBI-822. 

"We are very pleased with the success of our alliance with Stellar Biotechnologies, and the progress made towards commercial scale production of KLH for OBI-822," said Tessie Che, General Manager and Chair of Amaran's Board of Directors. "All of the programs that support OBI-822 and that will move this important immunotherapy closer to market launch are on track."

"Stellar's collaboration with Amaran is an exciting clinical project," said Catherine Brisson, Ph.D., Chief Operating Office for Stellar Biotechnologies, Inc. "Through close cooperation with the Amaran team, we achieved each primary objective on-time and to the particular specifications required. We look forward to the scale-up stage with Amaran and to providing our partners with GMP Stellar KLH™ for their immunotherapy programs."

About Amaran Biotechnology, Inc.

Amaran Biotechnology, Inc. is a privately-held Taiwan biopharmaceuticals manufacturer. Amaran is engaged in the business of designing, developing, and manufacturing pharmaceuticals and biotechnology products. It is expected that Amaran will manufacture KLH-conjugated active immunotherapies, such as OBI-822, the lead immunotherapy product of OBI Pharma, Inc. Visit www.amaran.com.tw to learn more about Amaran.

About OBI Pharma

OBI Pharma, Inc. is a Taiwan biopharmaceutical company established in 2002. OBI's mission is to develop novel therapeutic agents for unmet medical needs, including cancer & infectious diseases. The company's flagship product is OBI-822, a first-in-class active immunotherapy for metastatic breast cancer. OBI is also developing next generation active immunotherapies for difficult to treat cancers, including lung, prostate, pancreatic, stomach, and ovarian. The company is the license holder for DIFICID™ in Taiwan and owns the commercial rights to the product, a novel antibiotic indicated for C. difficile-associated diarrhea. Additional information can be found at www.obipharma.com/en.

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.

Contact Information:

Stellar Biotechnologies Company Contact:
Mark A. McPartland
Vice President of Corporate Development and Communications
Phone: +1 (805) 488-2800 ext. 103

Investor Inquiries:
Joseph Green
The Ruth Group
Phone: +1 (646) 536-7013

Media Inquiries:
Joanna Zimmerman
The Ruth Group
Phone: +1 (646) 536-7006